Review article: Management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 8, 2006, Pages 1133-1149

  Zeuzem, S ^a   Alberti, A ^b   Rosenberg, W ^c   Marcellin, P ^d   Diago, M ^e   Negro, F ^f   Prati, D ^g   Puoti, C ^h   Roberts, S K ⁱ   Shiffman, M L ^j  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d BEAUJON HOSPITAL   (France)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g A MANZONI HOSPITAL   (Italy)

^h Marino Hospital Rome   (Italy)

ⁱ ALFRED HOSPITAL   (Australia)

^j VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; AMANTADINE; BETA INTERFERON; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; EMBASE; ENZYME ACTIVITY; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; LIVER HISTOLOGY; LIVER INJURY; MEDLINE; MYALGIA; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON-ALPHA; LIVER; MOTIVATION; POLYETHYLENE GLYCOLS; PROGNOSIS; RIBAVIRIN;

EID: 33748883014     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03073.x     Document Type: Review

References (136)

1. National Institutes of Health Consensus. Development Conference Statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (5 Suppl. 1): S3-20.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
3. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 (Suppl. 1): 9-16.
4. Tassopoulos NC. Treatment of patients with chronic hepatitis C and normal ALT levels. J Hepatol 1999; 31 (Suppl 1): 193-6.
5. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36 (5 Suppl. 1): S179-84.
6. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137 (12): 961-4.
7. EASL International Consensus. Conference on Hepatitis C Paris, 26-28, February 1999, consensus statement. European Association for the Study of the Liver. J Hepatol 1999; 30: 956-61.
8. Brillanti S, Foli M, Gaiani S, Masci C, Miglioli M, Barbara L. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341: 464-5.
9. Martinot-Peignoux M, Boyer N, Cazals-Hatem D et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001; 34: 1000-5.
10. Persico M, Persico E, Suozzo R et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000; 118: 760-4.
11. Shakil AO, Conry-Cantilena C, Alter HJ et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330-7.
12. Arase Y, Ikeda K, Chayama K et al. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy. J Gastroenterol 1999; 34: 594-9.
13. Serfaty L, Chazouilleres O, Pawlotsky JM, Andreani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996; 110: 291-5.
14. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
15. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
16. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
17. Alberti A, Benvegnu L, Boccato S, Ferrari A, Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004; 36: 646-54.
18. Puoti C. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003; 38: 529-32.
19. Von Wagner M, Lee J-H, Friedl R, Kronenberger B, Sarrazin C, Zeuzem S. Impaired quality of life in patients with chronic hepatitis C and persistently normal transaminase levels. Hepatology 2003; 38 (4 Suppl. 1): 454A: Abstract 606.
20. Barrett S, Goh J, Coughlan B et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001; 49: 423-30.
21. Zeuzem S, Diago M, Gane E et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
22. Dubois F, Francois M, Mariotte N et al. Serum alanine aminotransferase measurement as a guide to selective testing for hepatitis C during medical checkup. J Hepatol 1994; 21: 837-41.
23. Jamal MM, Abdelkarim BZ. Chronic hepatitis C with persistently normal aminotransferase levels: do we have an adequate definition? Am J Gastroenterol 2003; 98: 1455-6.
24. Di Bisceglie AM. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. Am J Med 1999; 107 (6B): 53S-5S.
25. Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
26. Halfon P, Imbert-Bismut F, Messous D et al. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002; 1: 3.
27. Conry-Cantilena C, VanRaden M, Gibble J et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
28. Inglesby TV, Rai R, Astemborski J et al. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999; 29: 590-6.
29. Shiffman ML, Stewart CA, Hofmann CM et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis 2000; 182: 1595-601.
30. Bruno S, Rossi S, Petroni ML, Villa E, Zuin M, Podda M. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus. BMJ 1994; 308: 697.
31. Naito M, Hayashi N, Hagiwara H et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994; 19: 871-5.
32. Prieto M, Olaso V, Verdu C et al. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology 1995; 22: 413-7.
33. Shindo M, Arai K, Sokawa Y, Okuno T. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995; 22: 418-25.
34. Silini E, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995; 21: 285-90.
35. Van Thiel DH, Caraceni P, Molloy PJ et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol 1995; 23: 503-8.
36. Okanoue T, Yasui K, Sakamoto S et al. Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study. Liver 1996; 16: 241-7.
37. Prati D, Capelli C, Zanella A et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 1996; 110: 178-83.
38. Puoti C, Magrini A, Stati T et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-8.
39. Mathurin P, Moussalli J, Cadranel JF et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-72.
40. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30: 1307-11.
41. Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med 2000; 109: 62-4.
42. Tsuji K, Yamasaki K, Yamanishi M, Kawakami M, Shirahama S. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study. J Gastroenterol Hepatol 2001; 16: 536-40.
43. Rai R, Wilson LE, Astemborski J et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35: 1247-55.
44. Sookoian S, Castano G, Frider B, Flichman D. How to distinguish normal liver from chronic hepatitis in anti-HCV positive individuals with normal alanine aminotransferase levels. Medicina (B Aires) 2002; 62: 226-30.
45. Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003; 38: 511-7.
46. Kyrlagkitsis I, Portmann B, Smith H, O'Grady J, Cramp ME. Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98: 1588-93.
47. Pasquale G, Sagnelli E, Coppola N et al. Is liver biopsy necessary for hepatitis C virus carriers with persistently normal aminotransferase levels? Eur J Gastroenterol Hepatol 2003; 15: 831-3.
48. Piton A, Poynard T, Imbert-Bismut F et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-9.
49. Prati D, Shiffman M, Diago M et al. How normal are 'normal' alanine aminotransferase (ALT) levels in patients with chronic hepatitis C? Data from the randomized, multinational peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS) trial in patients with persistently 'normal 'ALT levels [Abstract 532]. Hepatology 2004; 40 (Suppl. 1): 395A.
50. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
51. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
52. Puoti C, Castellacci R, Montagnese F et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 2002; 37: 117-23.
53. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-90.
54. Marcellin P, Martinot M, Boyer N, Levy S. Treatment of hepatitis C patients with normal aminotransferases levels. Clin Liver Dis 1999; 3: 843-53.
55. Dincer D, Okten A, Kaymakoglu S et al. Persistently normal alanine transaminase levels in chronic C hepatitis: what does it tell us? Hepatogastroenterology 2001; 48: 1397-400.
56. Gholson CF, Morgan K, Catinis G et al. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol 1997; 92: 1788-92.
57. Sakugawa H, Nakasone H, Nakayoshi T et al. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT. Hepatogastroenterology 2003; 50: 165-9.
58. Herve S, Savoye G, Riachi G et al. Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity? Eur J Gastroenterol Hepatol 2001; 13: 495-500.
59. Shiffman M, Zeuzem S, Diago M et al. Natural history of chronic hepatitis C (CHC) in patients with persistently normal ALT levels in the multinational peginterferon alfa-2a (40 KD) (PEGASYS®) plus ribavirin (COPEGUS®) study: comparison of baseline histology with baseline data from patients with elevated ALT levels enrolled in phase III studies. Hepatology 2004; 40 (Suppl. 1): 397A. Abstract 536.
60. Hagiwara H, Hayashi N, Mita E et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545-50.
61. Rossini A, Ravaggi A, Agostinelli E et al. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. Liver 1997; 17: 133-8.
62. Keating GM, Plosker GL. Peginterferon alpha-2a (40 KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels. Drugs 2005; 65: 521-36.
63. Rumi MG, De Filippi F, Donato MF, Del Ninno E, Colombo M. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 2002; 9: 71-4.
64. Yuki N, Hayashi N, Takehara T et al. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol 1994; 89: 1462-6.
65. Ohmiya M, Hayashi J, Ueno K et al. Effectiveness of interferon treatment for patients with chronic hepatitis C virus infection and normal aminotransferase levels. Dig Dis Sci 2000; 45: 1953-8.
66. Tassopoulos NC, Vafiadis I, Tsantoulas D et al. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study. J Interferon Cytokine Res 2002; 22: 365-9.
67. Puoti C, Bellis L, Castellacci R, Montagnese F, Bergami N, Petrone De Luca P. HCV carriers with persistently normal aminotransferase levels. Hepatology 2004; 40: 266-7; author reply 267-8.
68. Okanoue T, Makiyama A, Nakayama M et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 2005; 43: 599-605.
69. Sterling RK, Stravitz RT, Luketic VA et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 469-73.
70. Rumi MG, De Filippi F, La Vecchia C et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-6.
71. Morisco F, Del Vecchio Blanco G, Tuccillo C, Galli C, Cirino S, Caporaso N. Long-term observation of HCV-positive patients with normal ALT values: persistence of a clinically healthy state. Res Virol 1998; 149: 277-82.
72. Puoti C. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. J Hepatol 2005; 43: 534-5.
73. Alberti A, Morsica G, Chemello L et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-8.
74. Kodama T, Tamaki T, Katabami S et al. Histological findings in asymptomatic hepatitis C virus carriers. J Gastroenterol Hepatol 1993; 8: 403-5.
75. Morales TG, Sampliner RE, Bhattacharyya A, Alter MJ. Liver histology in anti-HCV-positive persons with normal or minimally elevated aminotransferases. J Clin Gastroenterol 1995; 21: 301-5.
76. Healey CJ, Chapman RW, Fleming KA. Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995; 37: 274-8.
77. Montalto G, Zignego AL, Ruggeri MI et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig Dis Sci 1997; 42: 1703-7.
78. Pradat P, Alberti A, Poynard T et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36 (4 Pt 1): 973-7.
79. Sangiovanni A, Morales R, Spinzi G et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998; 27: 853-6.
80. Lee SS, Sherman M. Pilot study of interferon-alpha and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Viral Hepat 2001; 8: 202-5.
81. Puoti C, Stati T, Magrini A et al. Liver histology in anti-HCV positive subjects with normal ALT levels. Ital J Gastroenterol Hepatol 1997; 29: 383-4.
82. Cividini A, Rebucci C, Silini E, Mondelli MU. Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology 2001; 121: 1526-7.
83. Puoti C, Bellis L, Martellino F et al. Occurrence of hepatocellular carcinoma in an apparently 'healthy' HCV patient. Eur J Gastroenterol Hepatol 2005; 17: 1263-4.
84. Gordon SC, Fang JW, Silverman AL, McHutchison JG, Albrecht JK. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000; 32: 400-4.
85. Stanley AJ, Haydon GH, Piris J, Jarvis LM, Hayes PC. Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Eur J Gastroenterol Hepatol 1996; 8: 869-72.
86. Hasan F, Asker H, Al-Khalid J et al. Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels. Digestion 2002; 65: 127-30.
87. Hirsch KR, Wright TL. The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels. Am J Med 2000; 109: 66-7.
88. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
89. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
90. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
91. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 17-24.
92. O'Brien C, Wintfeld N, Patel KK et al. The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2a (PEGASY®) and ribavirin (COPEGUS®). J Hepatol 2004; 40 (Suppl. 1): 147. Abstract 499.
93. Arora S, O'Brien CB, Zeuzem S et al. Treatment of patients with persistently 'normal' ALT levels with the combination of peginterferon alfa-2a (40 KD) plus ribavirin: impact on health-relatede quality of life. J Gastroenterol Hepatol 2006; 21: 406-12.
94. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40 kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21: 341-9.
95. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
96. Ideo G, Bellobuono A, Tempini S, Mondazzi L, Bellati G, Zanetti A. Poor efficacy of alpha interferon treatment in patients affected by chronic hepatitis C with normal or near normal ALT levels. Gastroenterology 1996; 110: 1215A.
97. Areias J, Pedroto I, Freitas T et al. Hepatitis C virus carriers with normal ALT activity: viremia, genotype and effect of interferon therapy. Gastroenterology 1996; 110: 1144A.
98. Orito E, Mizokami M, Suzuki K et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 1997; 12: 58-61.
99. Mamori S, Suzuki F, Hosaka T et al. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. J Gastroenterol 2004; 39: 776-82.
100. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Interferon treatment in patients with chronic hepatitis C with normal alanine-aminotransferase activity. Hepatogastroenterology 1999; 46: 1094-9.
101. Tran A, Longo F, Ouzan D et al. Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity. Scand J Gastroenterol 2000; 35: 433-7.
102. Rossini A, Ravaggi A, Biasi L et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997; 26: 1012-7.
103. Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362-9.
104. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (3 Suppl. 1): 133S-6S.
105. Duvnjak M, Pavic T, Virovic L, Hrabar D. [Therapy with interferon alfa and ribavirin in patients with chronic hepatitis C and normal levels of alanine aminotransferase]. Acta Med Croatica 2003; 57: 159-62.
106. Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut 2003; 52: 1644-8.
107. Erhardt A, Behlen-Wilm U, Adams O, Donner A, Heintges T, Haussinger D. Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. Dig Dis Sci 2003; 48: 921-5.
108. Jacobson IM, Ahmed F, Russo MW et al. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol 2004; 99: 1700-5.
109. Mangia A, Spinzi G, Vuturo O et al. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Aliment Pharmacol Ther 2004; 19: 331-7.
110. Brillanti S, Levantesi F, Nigro G, Vicari S, Roda E. Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels. Ann Intern Med 2003; 139: W83.
111. Consensus Development Panel: National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 1997; 26(Suppl. 1): 2S-10S.
112. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-7.
113. Koff JM, Younossi Z. Hepatitis C with normal liver enzymes: to treat or not to treat. Pro: most patients should be treated. Am J Gastroenterol 2004; 99: 972-3.
114. Reddy KR. Hepatitis C with normal liver enzymes: to treat or not to treat. Con: most patients should not be treated. Am J Gastroenterol 2004; 99: 973-5.
115. Holt AF, Zucker SD. Hepatitis C infection with normal transaminases: is the treatment worse than the disease? Gastroenterology 2004; 127: 677-9.
116. Van Thiel DH, Colantoni A, De Maria N. Treatment of HCV positive individuals with normal serum ALT levels. Hepatogastroenterology 1998; 45: 321-4.
117. Russo MW, Brown RS Jr. Should patients with chronic hepatitis C who have normal ALT levels be treated? Curr Gastroenterol Rep 2001; 3: 49-53.
118. Shiffman ML. Hepatitis C with normal liver enzymes: to treat or not to treat. A balancing view: a decision to be shared with patients. Am J Gastroenterol 2004; 99: 975-6.
119. Ahmed A, Keeffe EB. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 2004; 126: 1409-15.
120. Bacon BR. Chronic hepatitis C and normal ALT: considerations for treatment. Am J Gastroenterol 2004; 99: 1706-7.
121. Gea F. Treatment of chronic hepatitis C with peginterferon alfa-2A (40 KD) (PEGASYS) and ribavirin (COPEGUS): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. Hepatology 2003; 38 (4 Suppl. 1): 156A-818A.
122. Gane E, Pockros P, Farci P et al. Age and sustained virological response in patients with persistently 'normal' ALT and chronic hepatitis C treated with peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (COPEGUS). J Hepatol 2005; 42 (Suppl. 2): Abstract 562.
123. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kD)/ribavirin therapy. Hepatology 2006; 43: 954-60.
124. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
125. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.
126. Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285-93.
127. Jamal MM, Saadi Z, Morgan TR. Alcohol and hepatitis C. Dig Dis 2005; 23: 285-96.
128. Duberg AS, Nordstrom M, Torner A et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005; 41: 652-9.
129. Montella M, Crispo A, de Bellis G et al. HCV and cancer: a case-control study in a high-endemic area. Liver 2001; 21: 335-41.
130. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
131. Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel KK. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006; 13: 377-86.
132. Kronenberger B, Ruster B, Lee JH et al. Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. J Hepatol 2000; 33: 640-7.
133. + T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels. J Hepatol 2002; 36: 408-16.
134. Asselah T, Martinot M, Cazals-Hatem D et al. Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. J Viral Hepat 2002; 9: 29-35.
135. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40: 1442-9.
136. Renou C, Pol S, Halfon P, Caillat-Zucman S. Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? Gastroenterology 2002; 123: 1748-9; author reply 1749.